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Natriuretic and antihypertensive effects of potassium in DOCA-salt
hypertensive rats. The role of a natriuresis in the protective effect of
potassium against the development and maintenance of salt-induced
hypertension was studied. Uninephrectomized rats showed average
systolic pressures of 177 3 mm Hg after the 28 days of treatment with
DOCA while receiving a 1% NaCI solution to drink. The supplements of
0.2 and 1% KC1 solution could counteract the blood-pressure raising
effect of NaCI in a dose-related fashion: The average pressures on day
28 at these dosages were 131 3 and 120 3mm Hg, respectively. The
cumulative sodium retention was significantly less in the KCI-supple-
mented rats than the DOCA-salt rats. Exchangeable body sodium
(sodium "space") at weeks I and 4 was significantly increased in the
DOCA-salt rats as compared to those in the vehicle-treated rats. But,
the potassium supplement could reduce sodium "space" dose-relatedly
in the DOCA-salt rats. Overall, there was a close correlation between
the systolic pressures and sodium "space" at week 4 (r = 0.811, P <
0.01). The results suggest that potassium may attenuate the rise in blood
pressure during the DOCA-salt treatment in uninephrectomized rats,
mainly as a result of inhibition of sodium retention, by increasing renal
sodium excretion.
Effets natriuretique et antihypertenseur du potassium chez des rats
hypertendus par de Ia DOCA et du sel. Le role d'une natriurèse sur
l'effet protecteur du potassium contre Ic développement et Ic maintien
d'une hypertension induite par le sel a eté étudié. Des rats uninéphrec-
tomisés avaient des pressions systoliques moyennes de 177 3 mm Hg
aprés 28 jours de traitement avec de Ia DOCA tout en buvant une
solution de 1% de NaCI. Des supplements de 0,2 et de 1% de solution de
KCI pouvaient s'opposer a l'effet d'augmentation de Ia pression artér-
ielle du NaCI d'une facon dose dépendante: Les pressions moyennes au
jour 28 avec ces quantites Ctaient de 131 3 et 120 3 mm Hg,
respectivement. La retention cumulative de sodium était significative-
ment moindre chez les rats supplementés en KCI que chez les rats
DOCA-sel. Le sodium echangeable de l'organisme ("espace" sodium)
aux semaines I et 4 était significativement augmenté chez les rats
DOCA-sel, par rapport a celui des rats traités par Ic véhicule. Cepen-
dant, Ic supplement potassique pouvait diminuer "l'espace" sodium
d'une facon dose-dépendante chez les rats DOCA-sel. Globalement, il y
avait une relation étroit entre les pressions systoliques et "l'espace"
sodium a Ia semaine 4 (r = 0,811,P < 0,01). Ces résultats suggèrent que
le potassium pourrait attCnuer l'élévation de pression artérielle pendant
Ic traitement par Ia DOCA et le sd chez des rats uninéphrectomisés,
essentiellement en inhibant Ia retention sodée, par élévation de l'excré-
tion rénale de sodium.
Numerous clinical, epidemiological, and animal studies have
shown that an excess of dietary sodium is in some way related
to the development of "essential" hypertension [1—61. In con-
trast, a dietary potassium supplement is antihypertensive in
animals and humans, and protects against the hypertensigenic
effects of excessive dietary sodium [7—10]. Moreover, Meneely,
Ball, and Youmans [11] and Meneely and Ball [12] reported thaI
the life-shortening effects of a moderately high sodium intake
could be prevented by supplements of dietary potassium.
Although the precise mechanism of the antihypertensive action
of potassium remains controversial [13—18], the natriuretic
properties of potassium are thought to play an important role
[19—22].
Over the past 20 years, there has been a growing realization
of the importance of the relationship between extracellular fluid
(ECF) volume and arterial blood pressure [23—25]. Since ho-
meostasis of the ECF is maintained by a balance between salt
and water intake and urinary output, potassium-induced natri-
uresis might prevent the rise in the ECF volume in the early
period following a sodium load, leading to the attenuation of the
rise in blood pressure. The present animal studies were under-
taken to analyze the effect of potassium on the sodium balance
and the resultant blood pressure in salt-induced hypertension.
The results demonstrate that the potassium supplement can
have natriuretic actions enough to inhibit the increase in the
ECF volume with deoxycorticosterone acetate (DOCA)-salt
treatment, resulting in the attenuation of the rise in blood
pressure.
Methods
Experiment 1. Male Sprague-Dawley rats, 5 weeks old, were
anesthetized with sodium pentobarbital (2 mg/100 g, i.p.), and
the left kidneys of the rats were removed. Following nephrecto-
my, 14 days were allowed for compensatory renal hypertrophy
to occur before DOCA-salt treatment was begun. DOCA (Sig-
ma Chemical Company, St. Louis, Missouri) was administered
once a week (by subcutaneous injection of 0.4 ml of a suspen-
sion containing, per milliliter of water: 25 mg DOCA, 10.5 mg
methyl cellulose, 3 mg carboxymethylcellulose, 1 mg polysor-
bate 80, and 8 mg NaCl). Salt was given by substitution of 1%
NaCI solution for drinking water. Potassium was given as mixed
solutions of 1% NaCI and 0.2% KCI or of 1% NaCI and 1% KCI
substituted for drinking water. Control groups included 40
uninephrectomized rats that received weekly injections of the
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vehicle without DOCA to follow the changes in blood pressure
with growth. A total of 40 control rats were studied, divided as
follows: 20, water-treatment; 10, 1% NaCI solution-treatment;
10, a mixed solution of 1% NaCI and 1% KC1-treatment.
Systolic blood pressure was measured once a week in con-
scious, restrained rats by the tail-cuff method. Throughout the
study, animals were housed in a room with constant tempera-
ture (24 1°C), humidity (60 5%), and light from 6 A.M. to 6
P.M. The animals were weighed weekly.
To examine the effect of potassium on the development of
DOCA-salt hypertension, a total of 90 male rats were subjected
to 20 vehicle plus water-treatment, 10 vehicle plus 1% NaCl
solution-treatment, 10 vehicle plus a mixed solution of 1% NaCl
and 1% KCI-treatment, 20 DOCA plus 1% NaCI solution-
treatment, 10 DOCA plus a mixed solution of 1% NaCI and
0.2% KCI-treatment, and 20 DOCA plus a mixed solution of 1%
NaC1 and 1% KC1-treatment. Blood pressure was measured
over a period of 28 days. The effects of potassium on renal
sodium handling during the 28 days of DOCA-salt treatment
were determined by measuring urinary sodium excretion in six
1% NaCI-treated control rats, six 1% NaCI and 1% KCI-treated
control rats, ten DOCA-salt treated rats, ten 0.2% KCI-supple-
mented, and ten 1% KCI-supplemented, DOCA-salt rats. These
animals were housed individually in metabolic cages (Nalge
Co., Rochester, New York) equipped with drinking bottles and
food cups on the outside of the cage to avoid contamination of
urine collections. The rats remained in the cages continuously
throughout the 28-day period except for short periods on 1 day
out of 7 during which they were removed for blood pressure
measurements, DOCA injections, and weighings. Twenty-four-
hour urinary sodium and creatinine excretion was measured on
those 6 out of 7 days in which the animals were undisturbed.
Rats in the metabolic cages were allowed to drink ad libitum.
The animals were provided with distilled water and received a
purified basal diet (0.25% sodium and 0.72% potassium, Japan
Clea Co., Tokyo, Japan). Total 24-hr sodium intake was calcu-
lated from the volume of 1% saline or of mixed solutions of 1%
NaCI and 0.2% KCI or 1% NaCl and 1% KCI drunk, and the
amount of food consumed. Daily sodium or potassium excretion
was calculated from the urine volume and the urinary sodium or
potassium concentration (mEq/liter), as measured by flame
photometry. Daily sodium and potassium balance was ex-
pressed by total sodium and potassium intake minus urinary
sodium and potassium excretion, respectively. Since, in the rat,
daily sodium and potassium excretion in feces contributes only
slightly to overall balance (1 to 2% for sodium and 1 to 3% for
potassium [26]), the balance data in this paper closely reflect the
status of overall daily balance.
The determinations of plasma renin activity and plasma
aldosterone concentration were performed after the 28 days of
treatments in 14 DOCA-salt rats and 12 1% KCI-supplemented,
DOCA-salt rats. Plasma renin activity was measured by radio-
immunoassay of angiotensin I generated at pH 6.5 by a modifi-
cation of the method of Haber et al [27]. Plasma aldosterone
concentration was measured by radioimmunoassay [28], using a
commercial kit (CEA-IRE-SORIN).
Experiment 2. Thirty male Sprague-Dawley rats, 5 weeks old,
were also used in this study. Following nephrectomy, the rats
were divided into three groups. The rats in all three groups were
Time, weeks
Fig. 1.Effects of potassium loading on the systolic blood pressure in the
DOCA-salt-treated rats. The P values refer to comparisons to the
vehicle-treated control groups using Student's unpaired t test. Symbol
definitions are: •—S, DOCA + 1% NaCI (20); A--A, DOCA + 1%
NaC1 + 0.2% KCI (10); 0-O, DOCA + 1% NaCI + 1% KCI (20); z--A,
Water (20); •—U, 1% NaCI (10); D—, 1% NaCl + 1% KCI (10); *, P
<0.01; and *, P < 0.001.
injected subcutaneously with 10 mg of DOCA once a week for 4
weeks. Rats of group 1 were given 1% NaCl to drink ad libitum
during the study, and rats of group 2 were given 1% NaCl to
drink for the first 2 weeks and were then switched to a mixed
solution of 1% NaC1 and 1% KC1. Rats of group 3 were given a
mixed solution of 1% NaCI and 1% K-citrate to drink ad libitum
during the 4-week experimental period. Systolic blood pres-
sures were measured once a week.
Measurement of extracellular fluid volume. After 7 and 28
days of the experimental regimens, five or nine rats were
selected from each experimental group and exchangeable sodi-
um (sodium "space") was determined by the principle of
isotope dilution. Each conscious rat was injected intravenously
with 20 Ci of 24NaC1 dissolved in 0.5 ml saline. After a 30-mm
equilibration period, measurements of radioactivity were made
on samples of serum, with a scintillation well counter. Sodium
"space," expressed as percent of body weight, were calculated
as follows:
Na "space" (% body wt) =
24Na injected (cpm)
___________
24NaJml serum (cpm) X body wt (g) x 100.
The validity of the described method was established by
preliminary experiments with animals from the stock colony.
Sodium space was determined in three rats by the method of
isotope dilution: The animals were killed, the entire carcass was
homogenized, an aliquot was digested with nitric acid, and
sodium was measured in the digest using the flame photometer.
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Table 1. Effects of DOCA-salt and potassium on body weight (g)
Weeks of DOCA-salt administration
Week 0 Week I Week 2 Week 3 Week 4
Experiment 1
Vehicle-injected control rats
(N = 20)
1% NaCI-treated control rats
(N = 10)
1% NaCI plus 1% KCI-
treated control rats (N = 10)
DOCA-salt rats (N = 20)
0.2% KCI-supplemented
DOCA-salt rats (N = 10)
1% KCI-supplemented
DOCA-salt rats (N = 20)
Experiment 2
DOCA-salt rats (N = 10)
1% KCI-supplemented
DOCA-salt rats for the last 2
weeks (N = 10)
1% K-citrate-supplemented
DOCA-salt rats (N = 10)
In three rats sodium space represented 90, 92 and 88% of the
total body sodium as measured by chemical analysis of the
carcass.
Numerical results are expressed as mean 1 SE. Statistical
analysis of the data was performed using Student's paired and
unpaired (tests. Regression analysis was performed according
to standard procedures. Changes are reported as significant if
the P value was less than 0.05.
Results
Experiment 1. As shown in Figure 1, DOCA-salt administra-
tion produced a rise in systolic blood pressure from Ill 2 to
130 2 mm Hg (P < 0.01) within 7 days. Mean systolic blood
pressure continued to rise, reaching 177 3 mm Hg (P < 0.001)
after the 28 days of DOCA-salt. In contrast, 0.2 and 1% KCI
supplements in the DOCA-salt treated rats resulted in small, not
statistically significant, elevations of blood pressure above
control by days 21 and 28, respectively. By day 28 of DOCA-
salt administration, average systolic pressures were 131 3 mm
Hg in the 0.2% KCI-supplemented rats, and 120 3 mm Hg in
the 1% KCI-supplemented rats. Throughout the 4-week experi-
mental period, blood pressure remained unchanged in the three
control groups: 20 water-treated, 10 1% NaCI-treated, and 10
1% NaCI plus 1% KCI-treated rats.
The growth of the rats in the three experimental DOCA-salt
groups was less than those of the three control groups (Table 1).
But, mean body weight on the final testing day was almost the
same in the group of DOCA-salt treated control rats (270 6 g)
as in the 0.2% KCI-supplemented DOCA-salt rats (268 9 g),
but lower in the 1% KCI-supplemented rats (194 6 g).
As shown in Figure 2, daily fluid and total sodium intake,
daily urine volume, and daily sodium excretion were signifi-
cantly greater in both vehicle- and DOCA-treated rats given
KC1. Blood pressure in these animals follows a similar course to
that described for the group as a whole (Fig. I). To evaluate the
effect of KCI supplementation on renal sodium handling, daily
sodium balance was calculated by total sodium intake minus
urinary sodium. The data (Fig. 3) reveal that there was a greater
positive sodium balance between days I and 7 in the DOCA-salt
rats as compared to that of the 1% NaCl-treated, vehicle
injected rats (8.6 1.2 mEq vs. 4.9 0.3 mEq, P < 0.05).
Thereafter, such a significant difference in sodium retention
between the groups continued through the 28-day experimental
period. In the KCI-supplemented, DOCA-salt rats, however,
the cumulative sodium retention was less than that of the
DOCA-salt rats in the early period. Thus, an estimate of the
mean cumulative sodium retention during the first 2 weeks of
DOCA-salt treatment was 14.0 1.1 mEq in the DOCA-salt
rats and 5.0 1.2 mEq in the 1% KCI-supplemented, DOCA-
salt rats (P < 0.05); this reveals evidence of a natriuresis
induced by the potassium supplementation. Between days 15
and 28, however, the sodium balance was not significantly
different in the two groups. During this period, blood pressure
in the 1% KCI-supplemented group gradually increased, and
reached to 120 3 mm Hg on day 28, which was slightly higher
than the initial blood pressure of 112 2 mm Hg. The 0.2%
KCI-supplemented, DOCA-salt rats also showed a lesser posi-
tive sodium balance between days I and 7 as compared to that
of the DOCA-salt rats. Moreover, the cumulative sodium
retention between days 1 and 14 in 0.2% KCI-supplemented rats
did not significantly differ as compared to the 1% NaCI-treated,
vehicle injected rats, but it became greater by day 21, when
blood pressure started to rise, As a result, the cumulative
sodium retention was decreased dose relatedly with the potassi-
um supplement in DOCA-salt rats, although the supplementa-
tion of 1% KC1 solution did not influence sodium balance in the
vehicle-injected rats (Fig. 3). An estimate of the cumulative
sodium retention during the 4-week experimental period was
23.7 1.4 mEq in DOCA-salt, 19.2 0.7 mEq in 0.2% KCI-
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supplemented, and 16.4 1.4 mEq in 1% KC1-supplemented,
DOCA-salt rats. In addition, there was a positive correlation
between cumulative sodium retention and systolic blood pres-
sures after 28 days of DOCA-salt administration in all three
DOCA-salt groups (r 0.804, P < 0.01).
In Figure 4, the data of daily potassium balance are also
presented. In contrast to sodium excretion, potassium excre-
tion does not escape the effects of DOCA: Negative potassium
balance continued throughout the 28 days of DOCA-salt admin-
istration, while there was a significant positive potassium
balance in the vehicle-injected rats. In the 1% KC1-supplement-
ed rats, however, daily potassium balance showed the signifi-
cant positive balance throughout the 28 days of observation.
Then, serum potassium was significantly decreased in the
DOCA-salt rats compared to that of the vehicle-injected control
rats (3.5 0,2 mEq/liter vs. 5.0 0.1 mEq/liter, P < 0.001).
However, the KC1-supplemented rats showed almost the same
serum potassium concentration as that of the vehicle-treated
controls rats (4.7 0.5 mEq/liter in 0.2% KCI-supplemented
rats and 5.0 0.4 mEq/liter in 1.0% KC1-supplemented ones).
Neither 1% NaCI nor 1% NaCI plus 1% KCI changed serum
potassium concentration in the vehicle-injected rats: 4.7 0.4
and 4.9 0.3 mEq/liter, respectively. There was no significant
difference in serum creatinine of these experimental groups as
compared to that of the control group.
Plasma renin activity was significantly (P < 0.01) higher in
the 1% KCI-supplemented, DOCA-salt rats (0.56 0.12
ng/ml/hr) than in the DOCA-salt rats (0.23 0.03 nglml/hr).
There was no significant difference in plasma aldosterone
concentration between the DOCA-salt rats and the 1% KCI-
supplemented, DOCA-salt rats: 32.9 3.5 ngldl and 45.2 6.2
ng/dl, respectively.
Experiment 2. In this experiment, a mixed solution of 1% KCI
and 1% NaC1 was given to one group of rats (group 2) after
hypertension had developed following the administration of
DOCA-salt. Such potassium loading reduced the elevated blood
pressure and prevented any further elevation of blood pressure,
as shown in Table 2. The administration of potassium resulted
in a significant reduction of body weight (Table 1).
On the other hand, 1% K-citrate was added to the 1% NaC1
solution in the other group (group 3) during the 4-week adminis-
tration of DOCA. K-citrate appeared as effective to attenuate
the rise in blood pressure with DOCA-salt as KC1 (Fig. 1 and
Table 2). The administration of K-citrate also resulted in a
significant reduction of body weight (Table 1).
Sodium 'space". The results summarized in Table 3 are the
mean values of sodium "space" at weeks 1 and 4. In the
DOCA-salt rats, sodium "space" was significantly increased (P
< 0.01) during the 7 days of DOCA-salt administration, com-
pared with the vehicle-treated control rats. In contrast, the 1%
KCI-supplemented, DOCA-salt rats showed a lesser sodium
"space"at week 1 than the DOCA-salt-treated rats, while
sodium balance between days 1 and 7 was significantly less
positive in the 1% KCI-supplemented DOCA-salt rats than the
DOCA-salt treated rats. Sodium "space" at week 4 was also
significantly greater in the DOCA-salt rats (29.4 0.6% body
weight vs. 22.2 0.4% body weight in the vehicle-injected
control rats, P < 0.01). Furthermore, the supplements of 0.2%
and 1% KC1 could reduce dose-related sodium "space" in the
T5
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Time, days
Fig. 2. Dailyfluid intake, daily urine volume, daily total sodium intake,
and daily sodium excretion during the 28 days of the administration in
rats of thefive experimental groups. The groups are represented bye,
the 1% NaCI-treated, vehicle injected rats; D, the 1% NaCI plus 1%
KCI-treated, vehicle injected rats •, the DOCA-salt rats; A, the 0.2%
KCI-supplemented, DOCA salt rats; 0, and the 1% KCI-supplemented,
DOCA-salt rats.
DOCA-salt rats: 27.3 0.4% body weight and 26.0 0.1%
body weight, respectively.
In the vehicle-injected rats at weeks 1 and 4, a negative
correlation was found for sodium "space" when expressed as
milliliters per 100 g body weight, as compared with body weight
(r = 0,823, P < 0.01) (Fig. 5). In the DOCA-salt rats at weeks I
and 4, the relationship of sodium "space" to body weight lies
above the mean 1 SD of the slope of the relationship in the
vehicle-injected rats. In contrast, the relationship in the 1%
KCI-supplemented, DOCA-salt rats at weeks I and 4 lies within
the mean SD of the slope. In the 0.2% KCI-supplemented,
DOCA-salt rats, it lies on the mean 1 SD of the slope. Finally,
in all four groups, there was a close correlation between the
systolic pressures and sodium "space" at week 4 (r 0.811, P
<0.01) (Fig. 6).
Moreover, sodium space was significantly decreased com-
pared to DOCA-salt rats, either when 1% KCI was added to the
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1% NaCI solution after hypertension had developed following
the administration of DOCA-salt or when a mixed solution of
1% K-citrate and 1% NaCI was given through the entire
experimental period (Table 3).
Discussion
The findings of these animal studies indicate that the potassi-
um supplement can promote daily sodium excretion, prevent
the expansion of the ECF volume by the DOC A-salt, and thus
attenuate the rise in blood pressure and delay the onset of
hypertension. Potassium loading was also effective to reduce
blood pressure when it was given after DOCA-salt hypertension
had been established. Both KC1 and K-citrate added to the 1%
NaCl solution greatly inhibited the rise in blood pressure during
the administration of DOCA. K-citrate was generally as effec-
tive as KCI. Thus, potassium itself seems to have played an
important role in the antihypertensive effect in DOCA-salt
hypertension.
During the first week of DOCA-salt, and 0.2% and 1% KCI-
supplemented, DOCA-salt rats had a significantly lesser posi-
tive sodium balance than the DOCA-salt rats. Thus, the potassi-
um supplement could moderate the increase in sodium space"
in the early period following the 7 days of DOCA-salt adminis-
tration. As a result, blood pressure was not significantly in-
creased in the 0.2 and 1% KC1-supplemented, DOCA-salt rats
but was significantly so in the DOCA-salt rats.
During the second week of DOCA-salt, daily sodium balance
remained significantly less positive in the 1% KCI-supplement-
ed, DOCA-salt rats than the DOCA-salt rats. Despite a signifi-
cant rise in blood pressure, the DOCA-salt rats retained more
sodium than the 1% KCI-supplemented DOCA-salt rats, whose
pressures remained unchanged from control values, Koch,
Aynedjian, and Bank [29] have demonstrated that, in the
isolated perfused rat kidney, an increase in perfusion pressure
of 30 mm Hg or greater results in a natriuresis, that is, a
"pressure natriuresis." Despite the higher systolic blood pres-
sure of 35 mm Hg with the greater increment of the ECF
volume, the DOCA-salt rats showed a significantly lesser
sodium excretion than the 1% KCI-supplemented rats in our
experiments. This suggests that the blood pressure-sodium
Time, days
Fig. 3. Daily sodium balance, and weekly and total cumulative sodium
retention (mEq) in rats of the five experimental groups in metabolic
cages during the 28 days of the administration. Symbols are: *, P <
0.05 (vs. the 1% NaCI-treated, vehicle injected rats); and *, P < 0.05
(vs. the DOCA-salt rats).
Time, days
Fig. 4. Daily potassium balance and weekly and total cumulative
potassium retention (mEq) in rats of the five experimental groups in
metabolic cages during the 28 days of administration. Symbols are: *,
P < 0.05 (vs. the 1% NaCI-treated, vehicle-injected rats); and *, 0.05
(vs. the DOCA-salt rats).
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Table 2. Effect of DOCA-salt and potassium on systolic blood pressure (mm Hg)
Weeks of DOCA-salt administration
Week 0 Week 1 Week 2 Week 3 Week 4
DOCA-salt rats (N = 10) 109 1" 136 1 153 2
DOCA-salt rats supplemented
with 1% KCI for the last 2
weeks(N=lO) 109±1 136±2 153±1
1% K-citrate-supplemented
DOCA-salt rats (N = 10) 111 1 116 2 116 3
170 2
129±2
118 3
179 2
119±2
116 3
a Values are means SE.
Table 3. Effect of DOCA-salt and potassium on sodium space" (% body wt)
Week I N Week4 N
Vehicle-treated rats 26.1 0.4" 7 22.2 0.4 9
DOCA-salt rats 30.4 0.2" 6 29.4 0.6" 9
0.2% KCI-supplemented DOCA-salt rats None 27.3 0.4" 7
1% KCI-supplemented DOCA-salt rats 28.6 0.2" 5 26.0 Old 7
1% KCI-supplemented DOCA-salt rats for
the last 2 weeks None 26.7 0.6 7
1% K-citrate-supplemented DOCA-salt rats None 26.6 0.4" 8
"Values are means SE.
P < 0.01 (vs. vehicle-treated rats).
"P < 0.01 (vs. DOCA-salt rats).
P < 0.01 (vs. 0.2% KCI-supplemented DOCA-salt rats).
excretion curve for the kidney of the DOCA-salt rats had
shifted to the right, resulting in a blunted pressure natriuresis,
and that the potassium supplement could restore this blood
pressure-urinary sodium excretion relationship near to normal.
During weeks 3 and 4 of DOCA-salt, there was no significant
difference in the daily sodium balance as between th DOCA-
salt rats and the KC1-supplemented, DOCA-salt rats. During
this period, the 0.2 and 1% KCI-supplemented rats showed a
gradual but definite rise in blood pressure. Therefore, the
potassium supplement could moderate, but did not inhibit
completely, the antihypertensive action of DOCA per Se, and
thus, it could delay, rather than inhibit, the development of
hypertension.
Finally, sodium "space" at week 4 in the 0.2% and 1% KCI-
supplemented rats was lower, as compared to that in the
DOCA-salt rats. Moreover, there was the significant positive
correlation between sodium space" and systolic blood pres-
sure in all four groups. These findings are consistent with the
notion that both the rise in blood pressure after the DOCA-salt
treatment and the fall in pressure with the KCI supplement may
depend on changes in ECF volume, resulting from the antina-
triuretic action of DOCA and the natriuretic actions of
potassium.
Increase in body weight was not observed in the rats treated
with 1% KCI loading, although 0.2% KCI loading did not inhibit
the increase in body weight in DOCA-salt rats (Table 1). One of
the possible causes of this phenomenon with 1% KCI loading is
probably based on the reduction in food intake due to the
massive rate of KCI ingestion. To account for the observation
that KCI-loading could moderate the expansion of ECF volume
with DOCA-salt treatment, therefore, one might speculate that
the effects of potassium supplementation on the change in
sodium space with DOCA are due to an anorexinogenic effect
and the resultant decrease in fluid (and thus sodium) intake
rather than due to an effect on sodium excretion. The evidence
does not support such a suggestion, however, since KCI
supplementation could apparently increase fluid (and thus sodi-
um) intake in DOCA-salt rats as well as vehicle-injected rats.
Secondly, 0.2% KC1 supplementation did not reduce food
intake nor inhibit the increase in body weight in DOCA-salt rats
(Table 2), but it was associated with a definite increase in fluid
and sodium intake. Despite a lack of appearance of anorexino-
genic effect, moreover, 0.2% KCI supplementation could inhibit
the increase in sodium space with DOCA, thus resulting in the
attenuation of the increase in blood pressure in DOCA-salt rats.
Therefore, it is concluded that the effect of potassium on
sodium space should not be attributed to anorexia but to the
natriuresis.
In the present study, moreover, the effect of potassium
loading on ECF volume is estimated. We have evaluated
sodium space in relationship to body weight in these experimen-
tal rats to correct this factor. As an animal ages, there is an
increase in the relative contribution of fat to the body weight.
Relative to most tissues of the body, adipose tissue has less
plasma and less extracellular fluids. Thus, it has been shown
[30, 31] that a negative correlation exists between ECF (cx-
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pressed in ml/l00 g) and body weight in the rat, as observed in
the present study (Fig. 5). The weights at week 4 in the vehicle-
treated control rats were greater than at week I, and sodium
space at week 4 were less than at week 1. Even if body weight is
considered, sodium space in the DOCA-salt rats at weeks I and
4 was significantly greater (P < 0.05), as compared to the
vehicle-injected controls rats. Although the weights of the 1%
KCI-supplemented, DOCA-salt rats were less than those of the
DOCA-salt rats, sodium "space" in the 1% KCI-supplemented,
DOCA-salt rats was still significantly smaller than those of the
DOCA-salt rats, and thus, it suggests a marked decrease in ECF
in the 1% KCI-supplemented, DOCA-salt rats. Despite the
protective effect on blood pressure, sodium "space" appeared
to be moderately increased in the 1% KCI-supplemented,
DOCA-salt rats (26.0 0.1% body weight), as compared to the
vehicle-injected control rats (22.2 0.4% body weight) (Table
3). This delusional difference in sodium "space" may be due to
the lesser weights in the 1% KCI-supplemented, DOCA-salt
rats. When body weight is considered, the relationship of
sodium space to body weight in the 1% KCI-supplemented,
DOCA-salt rats lies within the mean 1 SD of the slope of the
relationship between the two parameters in the vehicle-injected
control rats (Fig. 5). In contrast, in the 0.2% KCI-supplement-
ed, DOCA-salt rats whose blood pressure at week 4 was
significantly higher as compared to the vehicle-injected control
rats and the 1% KCI-supplemented, DOCA-salt rats, the rela-
tionship of sodium "space" to body weight lies on the mean I
SD of the slope (Fig. 5). Evidence presented suggested that, in
the early hypertensive stage of DOCA-salt hypertension, the
appearance of ECF expansion occurred, which might have
exerted a pathogenic role in the development of hypertension
by affecting adrenergic mechanisms [32, 331 and/or reactivity of
vascular smooth muscle [34, 35]. The supplementation of 1%
KCI could prevent the early sustained elevation of ECF, and
subsequently normal ECF continued through the 28 days of
observation, leading to inhibition of the rise in blood pressure
with DOCA-salt. The supplementation of 0.2% KCI was not so
sufficient as to maintain ECF normal against DOCA-salt, and
thus, blood pressure gradually increased.
The mechanisms for the natriuresis induced by potassium
loading remain unknown [36]. In the present study, the natri-
uretic effect of KCI cannot be explained by changes in plasma
aldosterone, since plasma aldosterone concentration was rather
higher in the DOCA-salt rats given KCI, possibly resulting from
either the augmented renin-angiotensin system with volume
depletion or aldosterone-secreting action of potassium per Se.
Young et al [13] reported that the natriuresis induced by
potassium loading was accompanied by an increase in the
plasma potassium concentration, within physiological limits, in
dogs. In the present experiments, serum potassium concentra-
tion was significantly decreased after the DOCA-salt adminis-
tration, but the supplements of KCI prevented the fall in serum
potassium. By changing the potassium concentration of blood
perfusion proximal tubules Brandis, Keys, and Windhager [21]
showed that a l-mEq/liter increase in plasma potassium pro-
duced a 6 to 8% reduction in proximal tubular sodium reabsorp-
tion. Therefore, it is possible that the supplements of 0.2 and
1% KCI may promote the natriuresis by the 1.2- and 1.5-
mEq/liter increases in plasma potassium concentration in the
Body weight, g
Fig. 5. Relationship between sodium space in mI/100 g body weight (%)
and body weight (g). A significant negative correlation was found for
sodium space to body weight (r = —0.823, P < 0.01, y = —0.031x +
32.807) in the vehicle-treated control rats at weeks I (Eli) and 4 (•).
Shaded area represents the mean si of the slope of regression line.
The relationship between sodium space and body weight in the DOCA-
salt rats (dotted area) at weeks 1(0) and 4 (•), 0.2% KCI-supplemented
rats at week 4 (*), and 1% KCI-supplemented rats at weeks I () and 4
(A).
DOCA-salt rats, respectively. It should be noted that the
supplementation of KCI did not increase sodium excretion nor
decrease blood pressure in the 1% NaCI-treated, vehicle-
injected control rats, without changes in serum potassium
concentration.
Although the natriuretic properties of potassium are thought
to play the most important role in the antihypertensive effects of
potassium, several mechanisms have been demonstrated by
which potassium may moderate hypertension [13—18]. Firstly,
KCI loading has been known to inhibit renin secretion [20, 37].
In the present study, however, plasma renin activity was
significantly higher in the potassium-supplemented, DOCA-salt
rats, as compared to that in the DOCA-salt rats. The higher
PRA by potassium supplements may be due to the natriuresis
induced by potassium, via inhibition of sodium retention.
Secondly, potassium has been reported to have both direct and
indirect effects on the vascular system [38—4 1]. Potassium may
reduce the reactivity of the peripheral arterioles to vasocon-
strictor agents such as norepinephrine and angiotensin 11115].
The increased pressor response to intravenous angiotensin II in
rats maintained on a high-sodium diet does not occur among
rats receiving KCI in addition to NaCI [16]. Moreover, a recent
report showed that hyperactive central pressor responses in
DahI salt-sensitive rats could be corrected largely with KCI
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Fig. 6. Regression analysis between sodium space at week 4 and the
systolic blood pressures on day 28 in all groups.
Although the hypotensive effect of potassium may be multifac-
tonal, it should not be dissociated from the natriuretic effect of
potassium administration.
Reprint requests to Dr. T. Fujita, Department of internal Medicine,
institute of Clinical Medicine, University of Tsukuba, Niihari-gun,
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